Jan 19,2023

InventHelp Inventor Develops Improved Insulin Pen (IPL-617)

"I wanted to create a convenient and timesaving way to administer insulin with an insulin pen," said an inventor, from Greensburg, Indiana, "so I invented the T M R W (TOMORROW). My design would eliminate the need for priming and it would ensure that no air remains inside." The invention provides an improved design for an insulin pen. In doing so, it eliminates the need for priming before use. As a result, it increases efficiency. It would also conserve insulin. The invention features a convenient design that is easy to use so it is ideal for individuals with diabetes that use insulin pens.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jan 20,2023

The quest for a truly artificial pancreas

Recently, continuous glucose monitors and programmable insulin patch pumps have started to be called an ‘artificial pancreas’ system, as they are able monitor and manage glucose levels with minimal action from the patient. This artificial pancreas is generally all that is required for patients with type 2 diabetes to successfully manage their condition and allows for more flexibility in their days and activities. However, this system does not address glucagon deficiency, which affects type 1 diabetes patients but not type 2 diabetes patients due to differences in pathology. Insulin lowers blood glucose while glucagon raises it. Dual-hormone pumps are intended to supply both insulin and glucagon. Beta Bionics is currently seeking approval from the FDA for the iLet Bionic Pancreas, both as a stand-alone insulin pump and later as a dual-hormone pump.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 23,2023

Medi-Cal Members Can Now Get Innovative Digital Programs to Prevent, Treat, Reverse Chronic Conditions

Blue Shield of California Promise Health Plan is now offering its Medi-Cal members Wellvolution, a digitally based lifestyle medicine and mental health support program that can be personalized to address individual health needs and preferences. Wellvolution programs that Medi-Cal members can access includes Diabetes Prevention program of 12-weeks for eligible members, chronic-condition reversal for diabetes and obesity, mindfullness and mental health services as well as the tobacco cessation digital therapies.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day.

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants

Nemaura Medical announces initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the United Kingdom. The initial pilot program recruited 30 individuals that were classified as obese according to their BMI. The first cohort of 10 patients have been enrolled in the program for over 12 weeks. Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement.

CLINICAL STUDY

#cgm

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility

Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion supports increased demand for its incretin products that treat diabetes.

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

ABBOTT REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS; ISSUES 2023 FINANCIAL OUTLOOK

Fourth Quarter sales of $10.1 billion were negatively impacted by an expected year over year decline in COVID-19 testing-related sales. In Diabetes Care, FreeStyle Libre sales were approx. $1.1 billion in the quarter, including U.S. growth of more than 40 percent.

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

The year ahead in diabetes care: what to expect in 2023

After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

JDRF Canada and Diabetes Canada are joining forces to accelerate diabetes research towards cures

JDRF Canada and Diabetes Canada are excited to announce how their combined funding efforts are helping to move diabetes research forward faster through support of two innovative projects focused on cutting-edge research on beta cells and islet replacement therapy. These two projects, which are supported through the JDRF-CIHR Partnership to Defeat Diabetes, are being funded by CIHR, Diabetes Canada and JDRF Canada. The projects are five years in duration and involve a total diabetes research investment of $4 million.

View Analyst & Ambassador Comments
Go to original news
Jan 25,2023

Embecta opens new global headquarters in New Jersey

Embecta (Nasdaq:EMBC) announced today that it held a grand opening ceremony at its new global headquarters in New Jersey. The BD Diabetes business spinoff opened its new headquarters at 300 Kimball Drive, Suite 300, in Parsippany, New Jersey.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES